Efficacy and safety of a combination of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis

Author:

Leung Henry W. C.1,Leung John-Hang2,Chan Agnes L. F.2

Affiliation:

1. Department of Radiation Oncology, An Nan Hospital, China medical University, Tainan, Taiwan

2. Department of Pharmacy, An-Nan Hospital, China Medical University, Tainan, Taiwan

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Reference43 articles.

1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

2. Breast cancer research in Asia: Adopt or adapt Western knowledge?

3. Global Status of Advanced/Metastatic Breast Cancer 2005–2015 Decade Report. (cited 27 March 2017).ww.breastcancervision.com and www.abc-lisbon.org

4. Howlader N, Noone AM, Krapcho M, et al. eds. SEER Cancer Statistics Review. 1975–2013, Bethesda, MD: National Cancer Institute. based on November 2015 SEER data submission, posted to the SEER web site April 2016 (updated September 12 2016, 27 October 2016, date last accessed). http:// seer.cancer.gov/csr/1975_2013/

5. 453 Trends in survival in metastatic breast cancer

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3